138 related articles for article (PubMed ID: 17624254)
41. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China.
Cao B; Ji DM; Zhou XY; Zhao TP; Guo Y; Wang ZH; Cao JN; Hu XC; Hong XN
Hematology; 2011 Sep; 16(5):291-7. PubMed ID: 21902893
[TBL] [Abstract][Full Text] [Related]
42. Diffuse large-cell lymphoma of the testis.
Tondini C; Ferreri AJ; Siracusano L; Valagussa P; Giardini R; Rampinelli I; Bonadonna G
J Clin Oncol; 1999 Sep; 17(9):2854-8. PubMed ID: 10561362
[TBL] [Abstract][Full Text] [Related]
43. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
[TBL] [Abstract][Full Text] [Related]
44. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
45. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
Paul F; Rossi JF; Cartron G
Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
[TBL] [Abstract][Full Text] [Related]
46. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
47. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features.
Muniesa C; Pujol RM; Estrach MT; Gallardo F; García-Muret MP; Climent J; Salar A; Servitje O
J Am Acad Dermatol; 2012 Apr; 66(4):650-4. PubMed ID: 21816504
[TBL] [Abstract][Full Text] [Related]
48. [Intravascular lymphoma treated with anti CD20 monoclonal antibodies. Report of one case].
Alfaro J; Espinoza A; Manŕiquez M; Moyano L; González N; Larrondo M; Figueroa G
Rev Med Chil; 2004 Nov; 132(11):1403-6. PubMed ID: 15693204
[TBL] [Abstract][Full Text] [Related]
49. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
50. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
[No Abstract] [Full Text] [Related]
51. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.
Abou Mourad Y; Taher A; Shamseddine A
Hematol J; 2003; 4(3):222-4. PubMed ID: 12764356
[No Abstract] [Full Text] [Related]
52. [A case of primary testicular malignant lymphoma associated with contralateral testicural recurrence after a seven-year interval].
Kato M; Soga N; Yamada Y; Kise H; Arima K; Sugimura Y
Hinyokika Kiyo; 2007 Sep; 53(9):671-5. PubMed ID: 17933148
[TBL] [Abstract][Full Text] [Related]
53. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
54. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
55. Rituximab for BCL-2-positive cancers.
Boughton B
Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
[No Abstract] [Full Text] [Related]
56. [Seven patients with stage I and II primary testicular lymphoma].
Kondo T; Wada H; Yata K; Mikami M; Tsujioka T; Suemori S; Suetsugu Y; Nakanishi H; Otsuki T; Yamada O; Yawata Y; Morioka M; Tanaka H; Sadahira Y; Sugihara T
Rinsho Ketsueki; 2002 Jun; 43(6):473-6. PubMed ID: 12134704
[TBL] [Abstract][Full Text] [Related]
57. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
[TBL] [Abstract][Full Text] [Related]
58. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
59. Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report.
Peruzzi P; Ray-Chaudhuri A; Slone WH; Mekhjian HS; Porcu P; Chiocca E
J Neurosurg; 2009 Aug; 111(2):247-51. PubMed ID: 19216652
[TBL] [Abstract][Full Text] [Related]
60. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
